Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - November 2013

Cell Based Assays

18 Nov 2013 - 19 Nov 2013 - London, UK

Bookmark and Share

SMi is proud to present their 6th Annual...

Cell Based Assays

Following on from our hugely successful Cell-Based Assays conference in 2012, this year's agenda will provide a global forum for senior level decision makers and those working within Cell-Based Assays to meet.

Highly accurate in-vitro practices are becoming absolutely vital as is looking at cost-effective assay development. Cell based assays now play an important role into the research pipeline, making a large percentage of total research time and is set to show considerable growth over the coming years.

There are currently 15 FDA approved kinase inhibitor drugs, but there currently remains a huge uncapped potential with these drugs as over 90% of the kinome is unknown. Novel assays have identified kinase targets, improved the function of kinase inhibitors and led to an acceleration in drug discovery with new inhibitor classes.

See at Cell Based Assays 2013 how HCA can be utilised in your pre-clinical toxicology procedures to give highly accurate data.


Hear the latest on Phenotypic screening; how target based screening is allowing for identification of small molecules

See how you can implement a primary cell assay plan through a case study of SARdriving assay

The latest in GPCR and other ion channel targeting pathways and how they are being used in the most recent drug discovery assays

Adopt accelerated primary cell screening systems such as those utilised by GSK


Mao Xiang Chen, Biological and Cellular targets, GlaxoSmithKline

Martha Brown, Senior Associate Director, Boehringer-Ingelheim

Xavier Leroy, Director, Actelion

Steve Ludbrook, Section Head, GlaxoSmithKline

Urs Luethi, Senior Lab Head Discovery, Actelion

Anthony Davies, Director, Trinity College Dublin

Tyrell Norris, Team Leader – Cellular Reagents & Assay Development, AstraZeneca

Amir Gander, Senior Knowledge Transfer Associate, University College London

**Book by 19th July 2013 and save £300**

**Book by 31st September 2013 and save £100**

Visit our website here:

Alternatively, contact Fateja Begum on +44 (0)20 7827 6184 or email:

Further information
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos